Prof Joseph Mikhael talks to ecancer following his MyKE Myeloma 2021 presentation.

He begins by saying that triple class refractory multiple myeloma is a real challenge for clinicians today in multiple myeloma. This is happening earlier and earlier in the disease course as patients are treated with more effective combinations earlier in the disease.

Prof Mikhael then goes on to talk about the various options that are available that were discussed during his session. Covering selinexor, belantamab mafodotin, melphalan flufenamide and CAR T-cell therapy.

He concludes by explaining that options for triple class refractory multiple myeloma are growing. More agents are available now than ever before and we will likely have many more in the future.